Biotech2050 Podcast: Recent Episodes
Jean Merlain
Biotech 2050 Podcast is a think tank chronicling the disruptions changing the biotech industry over the next 50 years.
James Burns, PhD, Chief Executive Officer, Locanabio
James (Jim) Burns, Ph.D., joined Locanabio in December 2019 as CEO and Board member. Prior to joining Locanabio, Dr. Burns served as the CEO of Casebia Therapeutics and led the team in discovering and developing new CRISPR/Cas9-based breakthrough therapeutics to treat blood disorders, blindness and auto-immune disease. Prior to Casebia, Dr. Burns spent the bulk of his career at Sanofi-Genzyme, where he held several leadership roles with increasing responsibility, including North America Site Head for R&D where he coordinated R&D operations across key therapeutic areas, and head of Sanofi-Genzyme R&D. Dr. Burns is a former board member of MassBio, a member of the U.S. National Academy of Engineering and a member of the External Advisory Committee for the BioMedical Engineering Department at Boston University. He also served as the industry representative for the Food and Drug Administration General Plastic Surgery Panel. Dr. Burns earned a Bachelor of Science degree in biology from Purdue University and Master of Science and Doctorate degrees in bioengineering from the University of Illinois-Chicago, where his thesis work focused on drug delivery. Following his graduate studies, he was a post-doctoral researcher at the University of Florida.
Kathie Bishop, PhD, Chief Scientific Officer, Locanabio
Kathie M. Bishop, Ph.D., joined Locanabio in August 2019 as CSO. Dr. Bishop has 20 years’ experience in leading translational research and drug development, with a focus on novel therapeutics in neurological and rare diseases. She was previously CSO at Otonomy, where she led preclinical and clinical development of a pipeline of neurotology programs. Before that, she was CSO of Tioga Pharmaceuticals. From 2009 to 2015, Dr. Bishop served in various product development management roles at Ionis Pharmaceuticals including Vice President, Clinical Development. At Ionis, she led translation and development of multiple programs in the neurology franchise including leading the development and clinical trials for SPINRAZA™ (nusinersen), the first approved treatment for patients with spinal muscular atrophy and winner of the 2017 Prix Galien Award. Dr. Bishop also served in research and development leadership roles from to 2001 to 2009 at Ceregene, a company focused on the development of AAV-based gene therapy products for the treatment of neurodegenerative and retinal disorders. She conducted post-doctoral work at the Salk Institute for Biological Studies and obtained her Ph.D. from the University of Alberta.
Victor Hanson-Smith is the Head of Computational Biology at Verge Genomics and is one of the world's leaders in mathematical modeling of eukaryotic genome evolution and function. He has co-authored 13 publications in peer-reviewed journals such as Nature and Science, and his work has been featured in the NYTimes and The Washington Post. He received his Ph.D. in Computer Science from the University of Oregon, and completed an NIH post-doctoral research fellowship in Evolutionary Genomics at UCSF. Additionally, he is a full-stack software engineer with 17 years experience building web applications, supercomputing simulations, and genomics pipelines.
Dr. Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company focused on accelerating drug discovery using synthetic biology. The company’s core technologies, ToRPPIDO and ToRNeDO, rely on genetic engineering and evolutionary selection to synthesize and identify compounds that disrupt protein-protein interactions or lead to selective target degradation. SyntheX was founded in 2016 and is located in San Francisco.
Maria has obtained her PhD from the Department of Molecular Genetics at the University of Toronto, where she discovered novel pathways linking metabolism and epigenetic signaling. Maria was previously a research scientist at a structural genomics consortium at the University Health Network in Toronto, where her work led to the determination of numerous structures and identification of several drug candidates.
Bob has been President of Imagion Biosystems since February 2015 and has led the company through the recent restructuring and recapitalization efforts. Previous employment experience includes Pres/GM for Silicon Biosystems and a career in marketing and sales management with more than 25 years experience in the computer, life science and medical diagnostics industries, e.g. Vice President Marketing and Sales for Nanogen, Inc., Senior Vice President of Marketing and Business Development at Gene Logic, and General Manager, Life Sciences at IGEN International, Inc. Mr. Proulx holds an M.A. and B.A. from The State University of New York at Albany and an Executive MBA from the Penn State Smeal College of Business.
Nick Damiano is a serial entrepreneur with broad experience in medical devices and digital health. He has 15 years of experience as a healthcare entrepreneur, engineer, and leader. He is currently Co-Founder & CEO of Zenflow, which is developing a novel office-based therapy to relieve symptoms of benign prostatic hyperplasia (BPH), which affects over 500 million men globally. The company has raised over $40 million in funding and conducted successful clinical trials in four countries. Zenflow is backed by leading venture firms including Invus and F-Prime and was one of the first medical device companies funded by Y Combinator, the world’s leading startup accelerator.
Prior to Zenflow, Nick was an Innovation Fellow at Stanford University. Before Biodesign, he co-founded Nurep (now called Avail MedSystems), a company developing telemedicine solutions for medical device procedures. In this role, Nick led the successful technical development effort to bring the company's product to market and also played key roles in strategy, sales, and fundraising. Prior to Nurep, he worked in engineering roles for several small medical device companies, including developing critical algorithms for the world’s first leadless cardiac pacing system at EBR Systems.
Outside of Zenflow, Nick plays an active role in mentoring and advising medtech and healthcare entrepreneurs and startups. He has served as an advisor in various capacities at StartX, Y Combinator Startup School, Stanford Byers Center for Biodesign, and the Rosenman Institute. He is also a Venture Partner at Pioneer Fund, a venture fund led by Y Combinator alumni.
Nick grew up on the east coast and earned his M.S. and B.S. with Distinction in Management Science & Engineering from Stanford University.
Colleen Cutcliffe is the CEO and Co-Founder of Pendulum. She has over 15 years of experience leading and managing biology teams in academia, pharmaceuticals and biotechnology. Prior to starting Pendulum, Colleen was the Senior Manager of Biology at Pacific Biosciences and a Scientist at Elan Pharmaceuticals. Colleen received her Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her B.A. in Biochemistry from Wellesley College.
Dr. Paul R. Billings is a board-certified internist and clinical geneticist, who also holds a PhD in Immunology, from Harvard University. He worked there with Dr. Baruj Benacerraf, who subsequently received the Nobel Prize in Medicine. In 2018, Dr. Billings became the Chief Medical Officer and Senior Vice President for Medical Affairs at Natera. Dr Billings recently has been a Partner in the diagnostic medicine consultancy the Bethesda Group, and the Managing Director of the Bethesda Group Fund. He is Chairman of PlumCare, LLc and Synergenz Biosciences Limited. He has held academic and research appointments at Harvard University, UC San Francisco, Stanford University and UC Berkeley. He co-founded the stem cell company, CBR Systems, was a Director at Ancestry.com and Signature Genomics Inc, and is co-founder and senior advisor of Fabric Genomics, Inc., a leading genome informatics firm. Until 2018, Dr. Billings was the Chairman of Biological Dynamics, a revolutionary molecular measurement platform based in San Diego, CA.
Andy Protter, PhD. joined Auransa in January 2017 as Chief Scientific Officer with 35 years of pharmaceutical industry research and development experience. At Auransa, Dr. Protter has led preclinical R&D which uses AI technology to discover novel drug candidates. Auransa’s lead project for hepatocellular carcinoma has completed all IND-supporting preclinical safety studies.
Prior to joining Auransa, Dr. Protter was a Vice President at Medivation where he was responsible for preclinical pharmacology and toxicology of Enzalutamide, a prostate cancer drug that was approved by the FDA.
Prior to Medivation, Dr. Protter worked at Scios, a biotechnology company where he also lead preclinical development. Dr. Protter initiated the Natrecor development program and was responsible for all preclinical activities. Natrecor was approved by the FDA for acute decompensated congestive heart failure. In addition Dr. Protter led preclinical efforts selecting a p38 MAP kinase inhibitor drug candidate that was tested in patients with rheumatoid arthritis and surgical pain. In 2004 Johnson and Johnson awarded Dr. Protter the Johnson Medal for his work on Natrecor.
Trained as a biochemist at the State University of New York at Stony Brook, Dr. Protter led the first successful cloning of apolipoprotein B, the primary protein on LDL. He has participated in work described in over 84 published papers, 4 book chapters and 28 patents.
When not doing science, Andy enjoys hobbies including biking, skiing, sailing, photography and reading.
Dr. Glenn Rosen has spent the bulk of his career engaged in basic and translational research in cancer and fibrosis. From 1993-2014, Dr. Rosen held a tenured faculty position in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, Stanford University. He led a basic and translational research laboratory-his research focused on the study of dysregulated signaling in fibrosis and mechanisms of apoptosis resistance in solid tumors. He also led the clinical Interstitial Lung Disease Program at Stanford. Dr. Rosen joined Bristol-Myers Squibb (BMS) in September 2014 as a Medical Director in the Early Clinical and Translational Research Group, where he led the Phase 2 program of a lysophosphatidic acid receptor antagonist for the treatment of pulmonary fibrosis. This was followed by appointment as Therapeutic Area Head of Fibrosis and Genetically Defined Diseases. In 2016 he was selected as Head, Discovery Fibrosis Biology at Bristol-Myers Squibb, where he led the early discovery and development, and translation of pre-clinical compounds, with a disease concentration in liver and lung fibrosis. Dr. Rosen joined Coherus Biosciences, Redwood City, CA, in April, 2019, where he leads the pre-clinical and translational sciences small molecule program, which is focused on development of a novel selective PPARγ modulator for the treatment of NASH.
JoyL is the General Manager of Pfizer CentreOne, a global contract development and manufacturing organization (CDMO) and a leading supplier of specialty APIs embedded within Pfizer. In 2019, under her leadership, Pfizer CentreOne contributed $810M in revenue with a growth rate of 9% while advancing Pfizer’s purpose of delivering breakthroughs that change patients’ lives. In 2020 Pfizer CentreOne received the Life Science Leader and Outsourced Pharma CMO Leadership Award for the fourth consecutive year, recognizing the strong partnerships built with customers.
JoyL began her 20+ year career at Pfizer as a healthcare representative and progressed through a series of sales, operational, and strategic leadership roles. Her roles as U.S. Regional Business Director and Commercial Enablement Lead included managing people leaders and demonstrating commercial excellence. Growing in both partnership and organizational management skills, JoyL then became the Global Integration Lead for the Pfizer/Merck KGaA Immuno-Oncology Alliance and Global Operations Lead for Pfizer Essential Health.
JoyL was recently named on the Medicine Maker Power List and Putnam Media Top 20 Influential Women in Manufacturing List. She has also received a Rising Star Award by the Healthcare Businesswomen’s Association and the Scrip Best Partnership Alliance Award.
JoyL has several industry publications, is a frequent speaker at professional forums and is a board member for the non-profit Pharma & Biopharma Outsourcing Association. A strong proponent of diversity, she is a sought-out mentor and sponsor.
JoyL is a graduate of the South Carolina Honors College at the University of South Carolina where she received a Bachelor of Science degree in Biological Sciences with a minor in Medical Humanities.
Nicole is Pfizer CentreOne’s Pipeline Development and Innovation Lead. In this role, Nicole has responsibility for assessing competitive intelligence to identify growth opportunities across the Pfizer CentreOne businesses, lead technical and regulatory assessments of pipeline projects and provide development services to meet customer needs. Nicole brings a wide range of expertise to this role, including a background which covers contract manufacturing operations, procurement, business development, and sourcing strategies.
Nicole joined Pfizer in 2001 as Pharmaceutical Supply Manager supporting the Parenteral Site in Carolina, Puerto Rico. In 2002, she was promoted to Category Manager in Global Procurement responsible for the identification and selection of contract manufacturers and packagers for pharmaceutical products. She joined External Supply (ES) in 2005 supporting the Divestitures and Business Development Group, and later on moved to manage contractors as an Operations Director. In 2010, Nicole was promoted to ES Strategy and Operations Management Director which included site divestiture support, sourcing, and leading the Americas Virtual Site governance. Nicole’s most recent assignment in Global External Supply included leading the implementation of SAP and partnering with tax and network strategy teams to roll out initiatives aligned with tax efficient system strategies and the standardizing/streamlining supply chain processes across the Global External Supply Virtual Sites.
Nicole holds a B.S. Degree in Chemical Engineering from The Georgia Institute of Technology and an M.B.A. from The University of Delaware.
Abbas Kazimi is the Vice President, Head of Business Development at Nimbus Therapeutics, a biotechnology company harnessing quantum mechanics and computational approaches to structural biology to design breakthroughs in medicine. Abbas joined Nimbus in 2014 as Director of Business Development and has driven several of the company’s key transactions that have brought over $775M into Nimbus through financings and transactions, including the exclusive licensing agreement with Genentech, the sale of Nimbus’ clinical NASH program to Gilead in and the multiple strategic alliances with Celgene.
Prior to joining Nimbus, Abbas spent a decade in planning, advising, and executing strategic transactions for life sciences clients with industry partners and financial investors across the globe, most recently at Extera Partners, LLC. He earned his M.A. from Harvard University and his B.A. from the University of Texas at Austin.
Dr. Randy Schatzman, Ph.D., is the chief executive officer and a board member of Bolt Biotherapeutics since 2019. He has over 30 years of biotechnology experience. Prior to Bolt, Dr. Schatzman was president and CEO, co-founder and board member of Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), from 2004 to 2018. Dr. Schatzman and his scientific team co-founded Alder in 2004 and led the company through the discovery and patenting of two monoclonal antibody therapeutics: eptinezumab, now in registration at FDA for migraine prevention and clazakizumab, being developed by Vitaeris for treatment of antibody-mediated kidney allograft failure. Prior to co-founding Alder, Dr. Schatzman was senior vice president of discovery research at Celltech R&D where the team discovered romosozumab which was subsequently licensed to Amgen in a 50/50 partnership. Prior to joining Celltech, he was at Syntex/Roche Bioscience where he served as preclinical team leader for Cytovene and team leader for Valcyte, both of which are currently marketed drugs. Dr. Schatzman received his Ph.D. in Molecular Pharmacology from Emory University before completing an American Cancer Society postdoctoral fellowship in the laboratory of J. Michael Bishop at the University of California, San Francisco. Dr. Schatzman is an inventor on over 30 issued patents and is an author on more than 40 peer-reviewed scientific publications.
Diego is currently the Head of Research & Development of Global Rare Diseases at the Chiesi Group. Before this role, he was leading Chiesi’s development projects in rare diseases and advanced therapies and has more than 10 years experience in drug development, spanning from pre-clinical to commercial phase.
Diego is an MD with a specialization in Internal Medicine. He obtained a PhD at the University of Parma (Italy) in cardiovascular pathophysiology and a post-doctoral fellowship in cardiovascular genomics at Stanford University (California, US).
Before joining the industry, he worked at the University of Parma (Italy) in the field of cardiovascular and metabolic genomics, and as free-lance consultant for various academic institutions.
He joined Chiesi in 2010, where he acted as Clinical Lead in the registration of the first stem cell therapy in EU and led the cross-company team (with uniQure BV) treating the first patient with a commercial gene therapy in EU. He also built an internal unit for the technical assessment of new in-licensing opportunities and the R&D infrastructure for due diligences.
Diego is serving as chairman of the Therapies Scientific Committee of IRDiRC (International Rare Diseases Research Consortium) and board member of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). He is the author of 50+ indexed papers and a frequent speaker at international medical and industrial congresses.
Dr. Clayman is a co-founder of Flexion Therapeutics and has served as our President, Chief Executive Officer and as one of our directors since our inception in 2007. Dr. Clayman also serves as the Chairman of the board of directors of both Anokion SA and Ribometrix. Previously, Dr. Clayman had a lengthy career at Eli Lilly and Company, where he was most recently Vice President, Lilly Research Laboratories, and General Manager of Chorus, Lilly’s early-phase development accelerator. During his career at Lilly, Dr. Clayman also led its Global Regulatory Affairs division, the Cardiovascular Discovery Research and Clinical Investigation, Research and Development at Advanced Cardiovascular Systems, a medical device subsidiary of Lilly, the Internal Medicine Division, the Lilly Clinic, Lilly’s dedicated Phase 1 unit, and served as Chair of Lilly’s Bioethics Committee. Prior to his tenure at Lilly, Dr. Clayman was an Assistant Professor in the School of Medicine at the University of Pennsylvania, where his research centered on the immunopathogenesis of renal disease. Dr. Clayman is the recipient of the Physician Scientist Award from the National Institutes of Health. Dr. Clayman earned a B.A., cum laude, from Yale University and an M.D. from the University of California, San Diego School of Medicine. Following an internship and residency in Internal Medicine at the University of California, San Francisco Moffitt Hospitals, Dr. Clayman completed clinical and research fellowships in Nephrology at the University of Pennsylvania.
Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. In addition to her role at InCarda, she is Executive Chairman (formerly CEO) of ProterixBio, and serves on the boards of CareDx (NASDAQ:CDNA) and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University. Formerly, she was a partner at New Science Ventures, a New York based venture capital firm with over $700M under management, and served on the boards of Paradigm Diagnostics and PerceptiMed.
Previously, she co-founded Pyranose Biotherapeutics, a biologics discovery platform company. She was also founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals. Prior to Intrexon, she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials. She also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., where she served clients in healthcare, biotech, high tech and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
Recorded in January 2020, we spoke with Sachin Chandran, who is currently Executive Director and Head of Pharmaceutical Sciences at Catabasis Pharmaceuticals, Inc. in Boston. Sachin’s responsibilities include oversight of CMC, Tech-Ops and supply chain along with matrixed interactions with regulatory, quality, biology, clinical and commercial. Working in a lean organization and a virtual environment, Sachin brings a strategic mindset while operationalizing with a can-do attitude with the goal to aid in the successful development and commercialization of edasalonexent.
Previously, Sachin has been at Vertex Pharmaceuticals, Inc. and Bristol Myers Squibb Co. in roles of increasing responsibility, courtesy of which he is well-versed in the development of oral dosage forms, biologics and injectables, and inhalation. Over the course of his career, Sachin has been involved in the advancement of new therapies for diseases such as Alzheimer’s, and rare diseases like Cystic Fibrosis and Duchenne Muscular Dystrophy.
Sachin holds a Ph.D. in Chemical and Biomolecular Engineering from the Johns Hopkins University where his graduate work was focused on new modalities in the treatment of prostate cancer.
Mike Novotny is the founder and CEO of Medrio. Mr. Novotny applies 20 years of experience in research and software to his eClinical SaaS vision. Prior to founding Medrio, Mr. Novotny was president of Ninaza, an EDC software company, and had previously held roles as a research associate at the U.N. and a manager of the fraud database at VISA. He holds a BA from Stanford University and an MBA from Columbia University. Mr. Novotny founded Medrio in 2005 in San Francisco.
David Mace is the Co-founder & CEO of SwiftScale Biologics, a life sciences startup based in San Francisco, California. SwiftScale Biologics accelerates time to market for protein drugs by turning a labor-intensive drug production scale-up challenge into a computational challenge. Previously David was an Entrepreneur in Residence at 8VC, where he focused on the intersection of biology & computer science. He is a graduate of the California Institute of Technology.
David Bates is a scientist, inventor, investor, and entrepreneur. He has co-founded several companies including Linus Health and Bode. He is a founding partner of Tamarisc Ventures and serves on the board of several high-growth technology companies. He is on the board of directors of TMCity Foundation and is Strategic Advisor to the Digital Medicine Society. He previously worked at Morningside Ventures where he focused on biotech, healthcare, and cleantech investments.
David was also the Chief Strategy Officer for F-Wave, a building technology company and Morningside portfolio company He helped with the acquisition of Fuji Solar in Japan and the company’s expansion from New Zealand into the United States.
David has held various positions as a research scientist at Harvard Medical School, Massachusetts General Hospital/Shriners Burns Hospital, University of Louisville School of Medicine, and the Georgia Institute of Technology. He has published in several high-impact journals and is a co-inventor on multiple technology and biotechnology patents. He holds a Ph.D. in Chemical and Materials Engineering from the University of Auckland and a B.S. and M.Sc. in Applied Biology from the Georgia Institute of Technology.
Stephan is a co-Founder and Chief Scientific Officer at Anokion, bringing more than 15 years of research expertise in the fields of immunology, protein engineering, and platform technologies to the company. He earned his B.Sc. in Chemical Engineering from the University of Texas at Austin and a Ph.D. in Bioengineering from the Swiss Federal Institute of Technology (EPFL) in Lausanne. During his thesis work, Stephan co-invented and developed the immune tolerance technology platform that inspired the founding of Anokion and its spin-off company Kanyos Bio. As a founding member of the executive leadership team, he has played a leading role in company creation, including raising equity capital, establishing transformative partnerships with pharmaceutical companies, and building teams and sites in the US and Switzerland. Stephan is an inventor of over 20 granted patents in the field of immune tolerance and continues to lead scientific innovation as head of Anokion's talented Research team.
Robert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. During his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a bachelor’s from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at Johns Hopkins University.
Owen Wallace joined Fulcrum in April 2017. He has more than two decades of experience in drug discovery and development across multiple therapeutic areas, including neuroscience, endocrine, infectious, respiratory and rare diseases. He is the co-inventor of seven clinical candidates and has overseen teams who have progressed more than 30 compounds into clinical development. Prior to joining Fulcrum, Owen served as head, global discovery chemistry at Novartis, where he was responsible for teams and projects across multiple sites in several disease areas and the chemical genetics field. Prior to Novartis, he was the site scientific leader with Eli Lilly & Company in the United Kingdom, leading a cross-functional team focusing on Alzheimer’s disease and schizophrenia. Before that, he held research positions at Bristol-Myers Squibb, where he co-initiated a program on a novel mechanism for inhibiting HIV infection that is now in Phase 3 clinical trials. Owen earned his Ph.D. in organic chemistry from Yale University.
Dr. Paul K. Wotton is Obsidian’s Chief Executive Officer, bringing significant experience spanning scientific research, product development and corporate growth gained over a thirty-year career. Dr. Wotton most recently served as the Founding President and CEO of Sigilon Therapeutics, Inc. Prior to Sigilon, Dr. Wotton served as President and Chief Executive Officer of Ocata Therapeutics until its acquisition by Astellas Pharma where he was also Co-Chairman of the Office of Integration. In previous roles, he served as President and Chief Executive Officer of Antares Pharma (NASDAQ:ATRS) as well as Chief Executive Officer of Topigen Pharmaceuticals. Dr. Wotton is a named inventor on numerous patents and was the Ernst & Young Entrepreneur of the Year Regional (NJ) Winner Life Sciences in 2014. He serves on the Boards of Directors of Vericel Corporation (NASDAQ: VCEL), Veloxis Pharmaceuticals A/S (Copenhagen: VELO) and Cynata Therapeutics (ASX: CYP) as its Chairman.
Chris is Sr. Vice President, Technical Operations at Blueprint Medicines. He has over 25 years of commercial and clinical manufacturing experience in the biopharmaceutical industry and has been fortunate to help develop and commercialize numerous oncology medicines. He has been in his current role since October 2017.
Carl P. Decicco is a biopharmaceutical veteran with over 30+ years of experience in the industry. Over the course of his career, Carl has played a central role in the advancement of more than 200 compounds into clinical trials and the approval of more than 20 drugs across multiple therapeutic areas. He’s authored/Co-Authored more than 100 scientific papers in peer reviewed journals and is listed as an inventor on 26 patents.
Dr. Florian Wegener is the co-founder and CEO of ZAGENO, an award-winning online marketplace serving the needs of research scientists. He is also a board-certified physician.
Raman is the founder and global president of ramarketing - an international design, digital and PR agency that's in the business of helping ambitious contract service companies operating in the global biotech and pharmaceutical outsourcing sector get noticed.
In this episode, guest Kevin Bittorf, founder of the Advancing Drug Development Forum and Dawn Dickerson sat down with host Alok Tayi to discuss trends in modern manufacturing and pharmaceutical environments.
Kevin Bittorf is an accomplished Senior Executive and Consultant with demonstrated success and a proven track record in pharmaceutical development, technical Innovation, and IoT.
Jon Hennek co-leads the Systems Innovation Team at Indigo Ag. He co-founded the team—whose mission is to create a vision for what agriculture could look like in the distant future and develop a strategy for the Indigo model to dramatically accelerate its adoption—in 2017 while at Flagship Pioneering.
Sven Karlsson is the co-founder, chief operating officer and chief business officer of Platelet BioGenesis. He has more than a decade of experience in business development and financial analysis.
Dr. Jo Viney is an entrepreneurial scientist and experienced biotech executive. A self-described “drug-hunter”, she has successfully advanced a number of programs into the clinic.
She is Co-Founder, President and CSO of Pandion Therapeutics, a startup company in Cambridge, MA focused on developing new therapies for treating autoimmune and inflammatory diseases.
John Keilty is the Chief Data Sciences Officer at Decibel Therapeutics and a Strategic advisor at Third Rock Ventures. He is a biologist and bioinformatics guy by training and has been active in the biotech space for over two decades. In his career, John has been responsible for building out genomix, and genetics capabilities for early stage biotech companies.
In this episode of Biotech 2050, John goes through his journey into the biotech industry and the work he’s doing at Decibel Therapeutics and Third Rock Ventures.
In this inaugural episode of Biotech2050, hosts Alok Tayi and Rahul Chaturvedi sits down with Lee Cooper, a seasoned biotech entrepreneur, patient advocate, and Founder of Enlight Bio to talk about the importance of patient centricity in today’s modern biotech.
Cooper talked about his journey to the Biotech industry and how he came to founding Enlight Bio.
This episode is a trailer launching our highly anticipated podcast, Biotech 2050. A Think Tank chronicling the disruptions changing the biotech industry over the next 50 years.